Cargando…
Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients
Heavy alcohol consumption can cause hyperhomocysteinemia, which could be consequential in the proinflammatory response and worsening of the neurobehavioral domains of alcohol use disorder (AUD), such as alcohol withdrawal. We examined the role of heavy drinking, hyperhomocysteinemia, gut dysfunction...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823569/ https://www.ncbi.nlm.nih.gov/pubmed/33374263 http://dx.doi.org/10.3390/biomedicines9010007 |
_version_ | 1783639866832060416 |
---|---|
author | Vatsalya, Vatsalya Gala, Khushboo S. Hassan, Ammar Z. Frimodig, Jane Kong, Maiying Sinha, Nachiketa Schwandt, Melanie L. |
author_facet | Vatsalya, Vatsalya Gala, Khushboo S. Hassan, Ammar Z. Frimodig, Jane Kong, Maiying Sinha, Nachiketa Schwandt, Melanie L. |
author_sort | Vatsalya, Vatsalya |
collection | PubMed |
description | Heavy alcohol consumption can cause hyperhomocysteinemia, which could be consequential in the proinflammatory response and worsening of the neurobehavioral domains of alcohol use disorder (AUD), such as alcohol withdrawal. We examined the role of heavy drinking, hyperhomocysteinemia, gut dysfunction and inflammation in early-stage alcoholic liver disease (ALD) in AUD patients. A total of 110 AUD patients without clinical manifestations of liver injury were grouped by the serum homocysteine levels (SHL): normal ≤ 13 µmol/L (Group 1 (Gr.1); n = 80), and elevated > 13 µmol/L (Group 2 (Gr.2), n = 30). A comprehensive metabolic panel, SHL, a nutritional assessment, and drinking history assessed by the timeline followback questionnaire were evaluated. A subset analysis was performed on 47 subjects (Gr.1 n = 27; Gr.2 n = 20) for additional measures: Clinical Institute Withdrawal Assessment for Alcohol (CIWA) score, plasma cytokines (interleukin-1β (IL-1β)), gut dysfunction markers (lipopolysaccharide (LPS), and LPS-binding protein (LBP)); 27% of the AUD patients exhibited hyperhomocysteinemia. SHL was significantly associated (p = 0.034) with heavy drinking days (HDD90). Subset analyses showed that the withdrawal ratings were both clinically and statistically (p = 0.033) elevated and significantly associated with hyperhomocysteinemia (p = 0.016) in Gr.2. LBP, IL1-β, SHL, and HDD90 showed significant cumulative effects (adjusted R(2) = 0.627) on withdrawal ratings in Gr.2 subset. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were significantly higher in all Gr.2 patients; AUROC showed a fair level of true positivity for ALT (0.676), and AST (0.686). Il1-β, LBP, SHL, and HDD90 showed significant cumulative effects (adjusted R(2) = 0.554) on the elevated ALT in Gr.2 subset as well. The gut-brain derived proinflammatory response, patterns of heavy drinking, and hyperhomocysteinemia were closely associated with clinically elevated alcohol withdrawal and elevated liver injury. Hyperhomocysteinemia could have a potential phenotypic marker response indicative of early-stage ALD along with AUD. |
format | Online Article Text |
id | pubmed-7823569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78235692021-01-24 Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients Vatsalya, Vatsalya Gala, Khushboo S. Hassan, Ammar Z. Frimodig, Jane Kong, Maiying Sinha, Nachiketa Schwandt, Melanie L. Biomedicines Article Heavy alcohol consumption can cause hyperhomocysteinemia, which could be consequential in the proinflammatory response and worsening of the neurobehavioral domains of alcohol use disorder (AUD), such as alcohol withdrawal. We examined the role of heavy drinking, hyperhomocysteinemia, gut dysfunction and inflammation in early-stage alcoholic liver disease (ALD) in AUD patients. A total of 110 AUD patients without clinical manifestations of liver injury were grouped by the serum homocysteine levels (SHL): normal ≤ 13 µmol/L (Group 1 (Gr.1); n = 80), and elevated > 13 µmol/L (Group 2 (Gr.2), n = 30). A comprehensive metabolic panel, SHL, a nutritional assessment, and drinking history assessed by the timeline followback questionnaire were evaluated. A subset analysis was performed on 47 subjects (Gr.1 n = 27; Gr.2 n = 20) for additional measures: Clinical Institute Withdrawal Assessment for Alcohol (CIWA) score, plasma cytokines (interleukin-1β (IL-1β)), gut dysfunction markers (lipopolysaccharide (LPS), and LPS-binding protein (LBP)); 27% of the AUD patients exhibited hyperhomocysteinemia. SHL was significantly associated (p = 0.034) with heavy drinking days (HDD90). Subset analyses showed that the withdrawal ratings were both clinically and statistically (p = 0.033) elevated and significantly associated with hyperhomocysteinemia (p = 0.016) in Gr.2. LBP, IL1-β, SHL, and HDD90 showed significant cumulative effects (adjusted R(2) = 0.627) on withdrawal ratings in Gr.2 subset. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were significantly higher in all Gr.2 patients; AUROC showed a fair level of true positivity for ALT (0.676), and AST (0.686). Il1-β, LBP, SHL, and HDD90 showed significant cumulative effects (adjusted R(2) = 0.554) on the elevated ALT in Gr.2 subset as well. The gut-brain derived proinflammatory response, patterns of heavy drinking, and hyperhomocysteinemia were closely associated with clinically elevated alcohol withdrawal and elevated liver injury. Hyperhomocysteinemia could have a potential phenotypic marker response indicative of early-stage ALD along with AUD. MDPI 2020-12-24 /pmc/articles/PMC7823569/ /pubmed/33374263 http://dx.doi.org/10.3390/biomedicines9010007 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vatsalya, Vatsalya Gala, Khushboo S. Hassan, Ammar Z. Frimodig, Jane Kong, Maiying Sinha, Nachiketa Schwandt, Melanie L. Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients |
title | Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients |
title_full | Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients |
title_fullStr | Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients |
title_full_unstemmed | Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients |
title_short | Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients |
title_sort | characterization of early-stage alcoholic liver disease with hyperhomocysteinemia and gut dysfunction and associated immune response in alcohol use disorder patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823569/ https://www.ncbi.nlm.nih.gov/pubmed/33374263 http://dx.doi.org/10.3390/biomedicines9010007 |
work_keys_str_mv | AT vatsalyavatsalya characterizationofearlystagealcoholicliverdiseasewithhyperhomocysteinemiaandgutdysfunctionandassociatedimmuneresponseinalcoholusedisorderpatients AT galakhushboos characterizationofearlystagealcoholicliverdiseasewithhyperhomocysteinemiaandgutdysfunctionandassociatedimmuneresponseinalcoholusedisorderpatients AT hassanammarz characterizationofearlystagealcoholicliverdiseasewithhyperhomocysteinemiaandgutdysfunctionandassociatedimmuneresponseinalcoholusedisorderpatients AT frimodigjane characterizationofearlystagealcoholicliverdiseasewithhyperhomocysteinemiaandgutdysfunctionandassociatedimmuneresponseinalcoholusedisorderpatients AT kongmaiying characterizationofearlystagealcoholicliverdiseasewithhyperhomocysteinemiaandgutdysfunctionandassociatedimmuneresponseinalcoholusedisorderpatients AT sinhanachiketa characterizationofearlystagealcoholicliverdiseasewithhyperhomocysteinemiaandgutdysfunctionandassociatedimmuneresponseinalcoholusedisorderpatients AT schwandtmelaniel characterizationofearlystagealcoholicliverdiseasewithhyperhomocysteinemiaandgutdysfunctionandassociatedimmuneresponseinalcoholusedisorderpatients |